Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

• Status: Unknown status
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to determine whether the STARFlex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the STARFlex® device compared to best medical therapy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NMT Medical
• Treatments: Acetaminophen

Criteria

Major Inclusion Criteria:

• Age 18-60 years inclusive.

• Positive contrast valsalva bubble study by trans-esophageal echocardiogram (TEE) for patent foramen ovale (PFO), with or without atrial septal aneurysm.

• Stroke or clinically definite TIA (contact study coordinator).

• Be able to comply with follow up over two years.

• Be competent to, or have a legal guardian competent to, provide informed consent following full disclosure of risks and benefits of both treatment arms by a study investigator.

• Venous access capable of accepting a 10F minimum vascular sheath.

• Have, or be willing to, discontinue hormonal based contraceptive use prior to enrollment and for the term of the study.

• Has cardiac anatomy based on enrollment echocardiogram that will allow for placement of the implant if randomized to the implant arm.

• Note: Additional inclusion criteria may apply. Contact study coordinator or principal investigator for details.

Post-randomization - device patients only

• The size of the PFO (measured by indentation with a soft balloon) must be amenable to selection of a STARFlex device.

Major Exclusion Criteria:

• Carotid artery stenosis > 50%.

• Intracranial stenosis > 50% appropriate to symptoms.

• Complex aortic arch atheroma with high risk features for embolism

• Aortic arch, carotid or vertebral artery dissection.

• Mitral or aortic valve stenosis, vegetation, or calcification > 5 mm mitral annular calcification (MAC) thickness.

• Active pregnancy.

• Active infections (contact study coordinator).

• Active infective endocarditis or bacteremia.

• Prosthetic heart valves in any location.

• Anterior MI within 3 months of neurological event.

• Chronic atrial fibrillation

• Thrombus in, or occluded, venous access route.

• Contraindication to heparin, aspirin, clopidogrel, or warfarin, or a known medical condition that requires continuous warfarin.

• Patient enrolled in another investigation study where clinical endpoint interference may occur.

• Permanent pacemaker or inferior vena cava (IVC) filter.

• Serum creatinine > 2.0 mg/dL

• Patients with known vasculitis or neurologic disorder.

• Baseline modified Rankin score of 3 or more.

• Hypercoagulopathies requiring long-term warfarin.

• Note: Additional exclusion criteria may apply.